A secondary analysis of results from a clinical trial of predictors of response to sertraline treatment for major depressive disorder (MDD) has found that a combination of magnetic resonance imaging (MRI) and clinical data can predict treatment response. These results were specific for sertraline treatment compared with placebo treatment.
A randomized trial involving patients with heart failure and depression has found that behavioral activation therapy and antidepressant treatment had comparable efficacy in reducing depressive symptoms. Behavioral activation therapy was more effective than medication on some secondary outcome measures.
Risperidone (generic) — Risperdal (brand)
A cohort study involving both publicly and commercially insured patients has found in adjusted analyses that exposure to stimulant medications during pregnancy did not significantly increase risk of childhood neurodevelopmental disorders. The investigators focused largely on children's risk of autism spectrum disorder (ASD) and attention-deficit hyperactivity disorder (ADHD). Study results were published online Jan. 24, 2024, in JAMA Psychiatry.
Hospitalized patients receiving haloperidol or ziprasidone for delirium while in intensive care experienced no increased risk of QTc interval prolongation relative to placebo, a secondary analysis of a randomized trial has found. None of the small number of cardiac events experienced by patients receiving one of the antipsychotics were determined to be associated with study drug administration.
Our coverage of emerging findings in psychopharmacology is generally limited to what gets published in the refereed scientific literature. Occasionally, however, something appears in the lay media that we think Update readers will benefit from knowing about. A recent such “something” was an article published in the New York Times under the alarming title “The F.D.A. [Food and Drug Administration] Warned an Asthma Drug Could Induce Despair. Many Were Never Told” (Jewett & Mueller, 2024). Broad coverage of this by other media outlets ensued.
A sequential randomized trial has found that both behavioral therapy and the sedative-hypnotic zolpidem improved daytime symptoms of insomnia, such as mood disturbances and functional impairments. Adding a second stage of therapy resulted in additional improvements in daytime functioning, the investigators found. Study results were published online Dec. 28, 2023, in JAMA Network Open.
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：